Therefore, we speculate that NCAM expression could be one of the determining factors for sensitivity of MM to Btz treatment and propose that the correlation between expression of NCAM and cytogenetic abnormalities with regard to Btz sensitivity warrants investigation using a larger sample size. Here, NCAM1 is linked to Miyoshi myopathy.